Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Wanner, Christoph; E. Inzucchi, Silvio; M. Lachin, John; Fitchett, David; von Eynatten, Maximilian; Mattheus, Michaela; Erik Johansen, Odd; J. Woerle, Hans; C. Broedl, Uli; Zinman, Bernard

doi:10.1056/nejmoa1515920

Public

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Published in New England Journal of Medicine • Jun 14, 2016

Authors:

Christoph Wanner

Silvio E. Inzucchi

John M. Lachin

Abstract

BACKGROUND: Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes at high risk for cardiovascula...

Subject

Empagliflozin

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!